Bill
S 1040
The Drug Competition Enhancement Act boosts access to affordable medications by easing entry for generics, lowering prices, and increasing market competition.
The Drug Competition Enhancement Act (S 1040) aims to promote competition in the pharmaceutical market by facilitating the entry of generic and biosimilar drugs. The bill seeks to lower drug prices for consumers by reducing barriers to market entry for these alternatives, thereby enhancing access to affordable medications.
The bill includes several significant provisions designed to enhance drug competition:
Streamlined Approval Process: The legislation proposes to simplify the regulatory pathway for generic and biosimilar drugs, making it easier for manufacturers to bring these products to market.
Increased Transparency: It mandates that pharmaceutical companies disclose certain pricing information, which is intended to provide consumers and healthcare providers with better insights into drug costs.
Market Exclusivity Adjustments: The bill seeks to modify the existing market exclusivity periods for brand-name drugs, potentially reducing the time frame during which generic competitors are barred from entering the market.
Incentives for Generic Manufacturers: The legislation includes provisions to incentivize the development of generics and biosimilars, particularly for drugs that have limited competition or are in high demand.
The Drug Competition Enhancement Act would have a broad impact on various stakeholders, including:
Consumers: Patients would benefit from potentially lower drug prices and increased access to affordable medications.
Pharmaceutical Companies: Both brand-name and generic drug manufacturers would be affected, with brand-name companies facing increased competition and generic companies gaining easier access to the market.
Healthcare Providers: Doctors and pharmacists would have more options to prescribe and dispense lower-cost alternatives to patients.
The legislative process for S 1040 has progressed as follows:
March 13, 2025: The bill was introduced in the Senate and referred to the Committee on the Judiciary.
April 3, 2025: The Committee on the Judiciary ordered the bill to be reported favorably with an amendment.
April 10, 2025: The bill was reported by Senator Chuck Grassley with an amendment and placed on the Senate Legislative Calendar under General Orders (Calendar No. 43).
The Drug Competition Enhancement Act (S 1040) represents a significant effort to enhance competition in the pharmaceutical industry, aiming to lower drug prices and improve access to medications for consumers. As the bill moves through the legislative process, its provisions and potential impacts will be closely monitored by stakeholders across the healthcare spectrum.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
